Novel juxtamembrane FLT3 in-frame insertion in a child with refractory AML: a case report of durable remission following allogeneic HSCT and FLT3 inhibitor therapy
FLT3 gene mutations, particularly internal tandem duplications ( FLT3 -ITD), are present in approximately 25%–30% of patients with acute myeloid leukemia (AML) and are important drivers of leukemogenesis; less frequently, FLT3 mutations occur as tyrosine kinase domain (TKD) variants. Non-canonical variants,...